NASDAQ: SNY
Sanofi Stock

SNY Price
$49.17
Fair Value Price
N/A
Market Cap
$122.48B
52 Week Low
$38.02
52 Week High
$53.77
P/E
43.90x
P/B
2.08x
P/S
2.97x
PEG
0.78x
Dividend Yield
3.54%
Revenue
$37.63B
Earnings
$2.81B
Gross Profit Margin
68.20%
Operating Margin
9.01%
Net Profit Margin
7.50%
Debt to Equity
0.91
Operating Cash Flow
$8B
Beta
0.65
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

High
Medium
Low
42
Industry average

Reasons for this score

SNY ($49.17) is trading below its intrinsic value of $211.60, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
SNY is poor value based on its earnings relative to its share price (43.90x), compared to the US market average (38.92x)
Valuation
SNY is good value based on its earnings relative to its share price (43.90x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

1 of 13

SNY News

Valuation

SNY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
43.90x
Industry
-11.07x
Market
38.92x
SNY is poor value based on its earnings relative to its share price (43.90x), compared to the US market average (38.92x)
Valuation
SNY is good value based on its earnings relative to its share price (43.90x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

SNY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.08x
Industry
7.85x
Market
65.04x
SNY is good value based on its book value relative to its share price (2.08x), compared to the US market average (65.04x)
Valuation
SNY is good value based on its book value relative to its share price (2.08x), compared to the US Drug Manufacturers - General industry average (7.85x)
Valuation

SNY price to earnings growth (PEG)

For valuing profitable companies with growth potential
SNY is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.78x)
Valuation

SNY's financial health

Profit margin

Revenue
$37.6B
Net Income
$2.8B
Profit Margin
7.50%
SNY's Earnings (EBIT) of $3.39B can safely cover interest payments on company debt ($25.93B)
Financials
SNY's profit margin has decreased (-4.60%) in the last year from (12.10%) to (7.50%)
Financials

Assets to liabilities

Assets
$112.7B
Liabilities
$53.6B
Debt to equity
0.44
SNY's short-term assets ($28.61B) exceed its short-term liabilities ($20.38B)
Financials
SNY's long-term liabilities ($33.25B) exceed its short-term assets ($28.61B)
Financials
SNY's debt has increased relative to shareholder equity (0.91), over the past 5 years ago (0.73)
Financials
SNY's debt to equity ratio (0.91) is considered high
Financials

Cash flow

Operating
$7.7B
Investing
-$1.2B
Financing
-$4.2B
SNY's operating cash flow ($7.74B) is sufficient to service the company's debt ($25.93B)
Financials

Sanofi Stock FAQ

(NASDAQ: SNY) Sanofi trades on the NASDAQ under the ticker symbol SNY. Sanofi stock quotes can also be displayed as NASDAQ: SNY.
(NASDAQ: SNY) Sanofi stock price per share is $49.17 today (as of Oct 21, 2020).
(NASDAQ: SNY) Sanofi's 52-week high was $53.77, and its 52-week low was $38.02. It is currently -8.55% from its 52-week high and 29.33% from its 52-week low.
(NASDAQ: SNY) Sanofi's market cap is $122.48B, as of Oct 22, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sanofi's market cap is calculated by multiplying SNY's current stock price of $49.17 by SNY's total outstanding shares of 1,245,454,385.
(NASDAQ: SNY) Sanofi currently has 1,245,454,385 outstanding shares. With Sanofi stock trading at $49.17 per share, the total value of Sanofi stock (market capitalization) is $122.48B.

Sanofi stock was originally listed at a price of $29.77 in Jul 1, 2002. If you had invested in Sanofi stock at $29.77, your return over the last 18 years would have been 65.17%, for an annualized return of 2.83%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics